FreeTrials & Tribulations Cabozantinib in first-line treatment of metastatic renal cell carcinoma Systemic therapies for metastatic renal cell carcinoma (mRCC) have expanded dramatically over the past 3 years.January 05, 2018Vol.44 No.01By Tian Zhang, Michael J. Morris, Darren R. Feldman, Toni K. Choueiri and Daniel J. George
